{
    "nctId": "NCT00873808",
    "briefTitle": "S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307",
    "officialTitle": "Long-Term Bone Quality in Women With Breast Cancer (A Companion Study to S0307)",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Change in bone quality after long-term high-dose bisphosphonates as measured by histomorphometry, mineralization density, micro-computed tomography, and biomechanics of bone biopsy samples",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Concurrently enrolled on clinical trial SWOG-S0307 and receiving bisphosphonates as adjuvant therapy for primary breast cancer\n* No rickets, osteogenesis imperfecta, osteosclerosis, or osteomalacia\n* No bone fracture since the age of 21 years unless it was caused by trauma\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Weight \\< 300 lbs\n* No hyperparathyroidism\n* No serious concurrent or prior anorexia nervosa diagnosed by a physician and causing abnormal menstruation\n* No history of hypersensitivity to tetracycline or demeclocycline\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 10 years since prior prednisone at a dose above 5 mg/day for \u2265 3 months\n* No prior prednisone before diagnosis of breast cancer\n* No prior bisphosphonate therapy\n* No concurrent anticonvulsant medications",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}